The impact of national viral hepatitis therapy program and hepatitis B vaccination program on mortality from acute and chronic viral hepatitis in Taiwan.
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Antiviral Agents
/ therapeutic use
Child
Child, Preschool
Female
Hepatitis B
/ mortality
Hepatitis B, Chronic
/ mortality
Humans
Immunization Programs
Infant
Infant, Newborn
Male
Middle Aged
Mortality
/ trends
National Health Programs
Sex Factors
Taiwan
/ epidemiology
Vaccination Coverage
Viral Hepatitis Vaccines
Young Adult
Acute and chronic viral hepatitis
Hepatitis B vaccination
Mortality
Journal
Hepatology international
ISSN: 1936-0541
Titre abrégé: Hepatol Int
Pays: United States
ID NLM: 101304009
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
22
08
2018
accepted:
14
01
2019
pubmed:
2
2
2019
medline:
18
7
2019
entrez:
2
2
2019
Statut:
ppublish
Résumé
In Taiwan, the national hepatitis B virus vaccination program and national viral hepatitis therapy program were implemented to control the infections of hepatitis viruses and their progressive illnesses. Studies have evaluated the impacts of two national health programs on many liver-related diseases, but not on acute and chronic viral hepatitis. The purpose of this study was to evaluate the impact on the mortality of acute and chronic viral hepatitis. Poisson regression models were used to estimate the adjusted rate ratios of the different period groups and corresponding 95% confidence intervals for childhood, adulthood and elderhood, and to estimate the adjusted rate ratios of vaccinated cohorts and corresponding 95% confidence intervals. Compared with period of 2000-2003, the adjusted rate ratios for period groups of 2008-2011 and 2012-2015 reported a significantly increasing risk of acute and chronic viral hepatitis mortality, except for the childhood and female adulthood. For population without vaccination, the adjusted rate ratios of acute and chronic viral hepatitis B mortality were 0.99 (95% CIs 0.88-1.12), 1.30 (95% CIs 1.17-1.45) and 1.42 (95% CIs 1.28-1.55) for periods of 2004-2007, 2008-2011 and 2012-2015, respectively, comparing with unimplemented period of national viral hepatitis therapy program. Compared with 1967-1983 cohorts, the adjusted rate ratio of 1984-2000 cohorts was 0.46 (95% CIs 0.28-0.75), and the adjusted rate ratios were 0.49 (95% CIs 0.28-0.87) and 0.35 (95% CIs 0.11-1.05) for male and female, respectively. This study revealed the significantly higher mortality rates of acute and chronic viral hepatitis during the implemented period of national viral hepatitis therapy program, comparing the unimplemented period. Such ineffectiveness may be attributable to the low coverage rate. The national vaccination program was currently an effective strategy for controlling the mortality of viral hepatitis.
Sections du résumé
BACKGROUND
BACKGROUND
In Taiwan, the national hepatitis B virus vaccination program and national viral hepatitis therapy program were implemented to control the infections of hepatitis viruses and their progressive illnesses. Studies have evaluated the impacts of two national health programs on many liver-related diseases, but not on acute and chronic viral hepatitis. The purpose of this study was to evaluate the impact on the mortality of acute and chronic viral hepatitis.
METHODS
METHODS
Poisson regression models were used to estimate the adjusted rate ratios of the different period groups and corresponding 95% confidence intervals for childhood, adulthood and elderhood, and to estimate the adjusted rate ratios of vaccinated cohorts and corresponding 95% confidence intervals.
RESULTS
RESULTS
Compared with period of 2000-2003, the adjusted rate ratios for period groups of 2008-2011 and 2012-2015 reported a significantly increasing risk of acute and chronic viral hepatitis mortality, except for the childhood and female adulthood. For population without vaccination, the adjusted rate ratios of acute and chronic viral hepatitis B mortality were 0.99 (95% CIs 0.88-1.12), 1.30 (95% CIs 1.17-1.45) and 1.42 (95% CIs 1.28-1.55) for periods of 2004-2007, 2008-2011 and 2012-2015, respectively, comparing with unimplemented period of national viral hepatitis therapy program. Compared with 1967-1983 cohorts, the adjusted rate ratio of 1984-2000 cohorts was 0.46 (95% CIs 0.28-0.75), and the adjusted rate ratios were 0.49 (95% CIs 0.28-0.87) and 0.35 (95% CIs 0.11-1.05) for male and female, respectively.
CONCLUSION
CONCLUSIONS
This study revealed the significantly higher mortality rates of acute and chronic viral hepatitis during the implemented period of national viral hepatitis therapy program, comparing the unimplemented period. Such ineffectiveness may be attributable to the low coverage rate. The national vaccination program was currently an effective strategy for controlling the mortality of viral hepatitis.
Identifiants
pubmed: 30706354
doi: 10.1007/s12072-019-09931-w
pii: 10.1007/s12072-019-09931-w
doi:
Substances chimiques
Antiviral Agents
0
Viral Hepatitis Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
157-164Références
Epidemiol Rev. 2006;28:126-35
pubmed: 16782778
Hepatol Res. 2007 Sep;37 Suppl 2:S101-5
pubmed: 17877468
J Clin Oncol. 2010 Oct 20;28(30):4587-93
pubmed: 20855826
J Hepatol. 2011 Feb;54(2):236-42
pubmed: 21030105
Gastroenterology. 2011 Oct;141(4):1240-8, 1248.e1-2
pubmed: 21703214
Liver Int. 2012 Apr;32(4):544-53
pubmed: 22099371
Kaohsiung J Med Sci. 2012 Jan;28(1):1-9
pubmed: 22226055
J Infect Dis. 2012 Mar 1;205(5):757-62
pubmed: 22262790
Kaohsiung J Med Sci. 2012 Sep;28(9):465-9
pubmed: 22974664
PLoS One. 2013 Jun 11;8(6):e65952
pubmed: 23776577
Sci Transl Med. 2013 Aug 7;5(197):197ra101
pubmed: 23926199
Med Care. 2013 Oct;51(10):908-13
pubmed: 23969591
JAMA. 2013 Sep 4;310(9):974-6
pubmed: 24002285
Hepatology. 2015 Apr;61(4):1154-62
pubmed: 25476749
Gerontologist. 2016 Apr;56(2):176-83
pubmed: 26589450
Clin Gastroenterol Hepatol. 2016 Sep;14(9):1324-30
pubmed: 27155556
Gastroenterology. 2016 Sep;151(3):472-480.e1
pubmed: 27269245
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
JAMA Oncol. 2017 Apr 1;3(4):524-548
pubmed: 27918777
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
Pharmacol Ther. 2018 Mar;183:118-126
pubmed: 29024739
Sci Transl Med. 2017 Oct 18;9(412):null
pubmed: 29046434
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403
pubmed: 29599078
J Formos Med Assoc. 2019 Jan;118(1 Pt 3):444-449
pubmed: 30017535
JAMA. 1987 May 15;257(19):2597-603
pubmed: 3573257